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REVIEW
Abstract: Osteoporosis is a major healthcare problem that continues growing as the population
ages. Sufferers become increasingly susceptible to fractures, which compromise physical and
emotional health and increase healthcare costs. Bisphosphonates are the most widely used
medicines for the treatment and prevention of postmenopausal osteoporosis. However,
therapeutic adherence is suboptimal, meaning that outcomes demonstrated in clinical trials
are not realized in the real world. It is anticipated that reducing dosing frequency may facilitate
medication intake and thereby improve adherence. Ibandronate is a potent nitrogen-containing
bisphosphonate specifically developed for administration with long dose-free intervals. The
comprehensive ibandronate preclinical development program has demonstrated dose-dependent
improvements or preservation of bone quality and strength. The feasibility of intermittent
dosing using the same total dose level as continuous dosing was also confirmed. In
postmenopausal osteoporosis, once-monthly oral ibandronate has been shown to be
therapeutically equivalent and even superior to daily oral ibandronate, which has demonstrated
antifracture efficacy for vertebral and nonvertebral fractures, bone mineral density gains at
the spine and hip, and reduction in bone resorption to premenopausal levels. Once-monthly
oral ibandronate is also associated with excellent safety and tolerability, and promises to further
improve therapeutic adherence to bisphosphonate treatment, thereby enhancing therapeutic
outcomes.
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Introduction
With the rapidly rising average age of the population, osteoporosis has become a
major healthcare problem. The disease, often a consequence of the menopause, is
characterized by low bone mass and microarchitectural deterioration of bone tissue
with a consequential increase in fragility and susceptibility to fractures (NIH 2000).
Although the disease is silent for years without or with only little physical restraint
for the patient, it results in substantial morbidity and mortality once the first fracture
has occurred. The health and financial impact of the rising incidence of osteoporosis
is of increasing significance. More than 2 million individuals in the US will experience
osteoporosis-related fractures in 2005, resulting in medical costs estimated to be
more than US$16.9 billion (Kuehn 2005). This figure is expected to increase over
the following decades due to demographic changes within the population.
Bisphosphonates are the most widely used prescription medicines for the treatment
and prevention of postmenopausal osteoporosis. The nitrogen (N)-containing
bisphosphonates alendronate and risedronate have demonstrated antifracture efficacy
when administered orally daily. Their weekly regimens are now the most frequently
prescribed. Whilst having proven efficacy and demonstrated tolerability and safety
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similar to placebo in controlled clinical trials, these
compounds are cumbersome to take since patients need to
follow stringent dosing requirements. Due to the very low
and highly variable oral bioavailability of bisphosphonates,
they have to be taken early in the morning after an overnight
fasting state, followed by a post-dose fasting period of at
least 30 minutes. In order to facilitate the esophageal passage
of the tablets and to prevent the frequent gastrointestinal
(GI) side effects due to local irritation of the GI mucosa,
patients also need to remain upright after intake of the
tablets. This is a significant hurdle for patients to continue
treatment to the degree necessary to achieve the
demonstrated outcomes of clinical trials. Consequently,
patient adherence to therapy can be assumed to be less than
optimal in daily life outside the controlled clinical trial
environment. There is an increasing body of evidence which
clearly highlights poor adherence to oral bisphosphonate
regimens (Cramer et al 2004; Ettinger et al 2004; Bartl et al
2005; Cowell, Corner, et al 2005; Cowell, Fulford-Smith,
et al 2005). Approximately half of all patients abandon their
treatment within 6 months of starting therapy, and for daily
regimens, only 15%–30% of patients remain on treatment
at the end of the first year. Such adherence cannot translate
into the protection promised by clinical trial results. One
way to address this is to facilitate the intake of the
bisphosphonates by reducing the dosing frequency (SG
2004). A first step has been taken with the development of
weekly regimens, which have clearly resulted in an
improvement in therapeutic adherence, but the overall rates
of patients staying on weekly treatment are still insufficient
(Cramer et al 2004; Bartl et al 2005), indicating the medical
need for further improvement.
Ibandronate is a highly potent N-containing bisphos-
phonate which has been developed with the aim of
improving the therapeutic effectiveness of bisphosphonate
treatment. Ibandronate combines the known efficacy of the
bisphosphonate class with good safety and tolerability and
more convenient long dose-free intervals, thus optimizing
the dosing frequency. This has resulted in the recent approval
of a unique once-monthly tablet of ibandronate for the
treatment and prevention of postmenopausal osteoporosis
in the US and the EU. This paper comprehensively reviews
the efficacy and safety of ibandronate from the preclinical
through to the clinical development stages.
Ibandronate
Ibandronate is a highly potent N-containing bisphosphonate,
which binds to bone mineral surface and inhibits osteoclasts,
the cells which are responsible for bone resorption.
Compared with other bisphosphonates, a high antiresorptive
potency means that lower doses are needed to achieve the
same efficacy with regard to inhibition of bone resorption.
The combination of its antiresorptive potency and the
excellent safety profile provides the basis for ibandronate
to be administered with increased doses and extended dosing
intervals without compromising tolerability.
Structure–activity relationship
Bisphosphonates are structural analogues of pyrophosphate,
in which the oxygen atom of the phosphorous-oxygen-
phosphorous (P-O-P) bond is replaced by a carbon atom
resulting in a phosphorous-carbon-phosphorous (P-C-P)
bond. Like all biologically active bisphosphonates,
ibandronate contains a core P-C-P structure (Figure 1)
essential for affinity to bone mineral and inhibition of bone
resorption (Russell et al 1999; Rogers et al 2000; Rogers
2003). Modification of the side-chain substituents
determines the therapeutic characteristics of the different
bisphosphonates. On its R1 lateral chain, ibandronate
contains a hydroxyl group, which enhances the strength of
skeletal binding and prevention of hydroxyapatite crystal
growth (van Beek 1994). The R2 side chain is the major
determinant of antiresorptive potency (Fleisch 1998); at R2
ibandronate contains one of the most potent structural
features, a tertiary nitrogen group. Due to its structural
attributes, ibandronate was found to be approximately 2,
10, 50, and 500 times more potent than risedronate,
alendronate, pamidronate, and clodronate, respectively
(Mühlbauer et al 1991).
Bisphosphonates are subdivided into 2 groups with
different molecular mechanisms of action (Russell et al
1999; Rogers et al 2000; Rogers 2003). In the first group
are etidronate and clodronate, which do not contain nitrogen
in their molecule. After incorporation by osteoclasts during
the bone resorption process, non-N-containing bisphos-
phonates either form cytotoxic metabolites or inhibit protein
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tyrosine phosphatases. Bisphosphonates in the potent, N-
containing group (including pamidronate, alendronate,
risedronate, ibandronate, and zoledronate) inhibit the
mevalonate pathway in osteoclasts, in particular the farnesyl
pyrophosphate synthase. This prevents post-translation lipid
modification (ie, prenylation) of small guanosine
triphosphatase signaling proteins required for osteoclast
function and cytoskeletal integrity. Both mechanisms of
action lead to apoptosis. Based on their mode of action, the
terminology for such bone antiresorptive drugs was recently
proposed to be changed to “anticatabolic” drugs (Riggs and
Parfitt 2005).
Pharmacokinetics
As with other bisphosphonates, ibandronate is poorly
absorbed by the GI tract after oral administration. Its oral
bioavailability in humans was estimated to be 0.63%, and
in rats and dogs ≤ 1% (Barrett et al 2004; Bauss and Russell
2004). Once they have entered the circulation, about
40%–60% of the bisphosphonate binds tightly to the bone
surface, while the remaining drug is excreted unchanged
by the kidneys. Ibandronate is not metabolized and uptake
by soft tissues is less than 2% of the systemic dose. Protein
binding is low (about 85%–87%) and there is no inhibition
or induction of the major cytochrome P450 isoforms, thus
drug–drug interaction is unlikely. Further details on the
pharmacokinetic properties of ibandronate in humans have
been reviewed and previously summarized (Barrett et al
2004).
Bone-binding kinetics
Due to strong binding to the bone surface, the effects of the
systemically available amount of a bisphosphonate are
almost exclusively related to its concentration in bone rather
than serum levels. When subcutaneously (SC) administered
daily over 1 year to rats, the concentration of ibandronate
in bone was found to be linearly related to the systemic
dose, suggesting linear kinetics in the tested dose range of
0.2–25 µg/kg/day, resulting in a total cumulative dose of
approximately 0.07–9.1 mg/kg (Bauss, Lalla, et al 2002).
Even after lifelong (2 years) oral ibandronate administration
with doses up to 15 mg/kg/day, bone uptake of ibandronate
in rats was linear with the dose, and no gender-related
differences were observed in adult animals (Endele et al
2005). A dose-dependent uptake into rat bone has also been
demonstrated for single doses of alendronate up to 5 mg/kg
(Lin et al 1992).
Bones consisting of predominantly trabecular bone, like
vertebrae, have a 2–3 times greater uptake of ibandronate
than those consisting of primarily cortical bone, like long
bones (Bauss, Lalla, et al 2002; Smith et al 2003). A higher
uptake by trabecular bone in comparison to cortical bone is
also reported for alendronate (Lin et al 1991). The release
kinetics from bone also seem to be similar for all
bisphosphonates, and the half-life for elimination from rat
bone is approximately 1 year depending on the type of bone
(trabecular vs cortical bone). In humans the elimination half-
life from bone was calculated to be approximately 10 years
for alendronate (Kahn et al 1997). These bone kinetic
characteristics provide the most important component of
intermittent treatment with ibandronate and serve as the basis
for understanding its long-lasting effects on bone.
Preclinical support for the
development of ibandronate
regimens with extended between-
dose intervals
Bone loss in estrogen-depleted (ovariectomized [OVX]) rats
and in postmenopausal women share many characteristics,
including pathophysiological changes and skeletal response
to different therapies (Kalu 1991; Frost and Jee 1992).
Consequently, drug approval authorities request the OVX
rat model as 1 of 2 animal models to be used for the
preclinical investigation of drugs intended for the prevention
and treatment of postmenopausal osteoporosis (FDA 1994;
CPMP 2001). However, in addition to the OVX rat, which
is regarded to be a modeling species, larger animals such as
OVX dogs and monkeys serve as a remodeling species, are
required. The World Health Organization (WHO) recently
acknowledged the value of these animal models as being
highly predictive for drug action in human postmenopausal
osteoporosis with regard to bone mass, remodeling, bone
architecture, and strength (WHO 1998). The more practical
aspects related to the WHO guidelines have previously been
reviewed (Bonjour et al 1999). The preclinical development
of ibandronate is fully aligned with drug approval authority
and WHO expectations.
Preclinical efficacy and total dose
concept of ibandronate
Bone mass and turnover
The efficacy of intermittent administration of ibandronate
has been demonstrated in 3 estrogen-depleted animal species
(rat, dog, and monkey). In these species, ibandronate doseTherapeutics and Clinical Risk Management 2006:2(1) 6
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dependently prevented or restored bone loss and depressed
increased bone turnover due to estrogen depletion, as
assessed by bone densitometry, mineral analyses in bone
ash, histomorphometry, and biochemical parameters of bone
turnover. A comprehensive review article by Bauss and
Russell (2004) provides the rationale for intermittent dosing
of ibandronate, summarizes the nonclinical osteoporosis
program, and compares the results with those published for
other bisphosphonates (Bauss and Russell 2004).
Several dose-finding studies have been carried out to
determine the optimal dosing of ibandronate. One such dose-
finding study in aged OVX rats confirmed that a daily SC
dose of 1 µg/kg/day ibandronate optimally prevented bone
loss (optimal in that results obtained with this dose were
not statistically different from those of age-matched sham-
operated controls), while higher doses resulted in a plateau
(Bauss, Wagner, et al 2002). A follow-up study in the same
model compared the daily dose of 1 µg/kg/day with 2
intermittent cycles (on/off weeks = 1/2, 1/4, and 1/6 ) with
all doses resulting in the same cumulative total dose. Daily
and all intermittent ibandronate regimens provided
equivalent results with regard to prevention of bone loss
and bone architecture. This total dose concept has also been
proven valid when 1-year treatment with daily (0.2–25 µg/
kg/day) and intermittent (25 and 125 µg/kg every 25 days)
dosing was initiated after considerable bone loss has been
demonstrated (Bauss, Lalla, et al 2002).
A study in fully-grown ovariohysterectomized (OHX)
beagle dogs found the optimal SC dose to prevent all
estrogen deficiency-related changes on bone mass and
architecture to be, as in rats, 1 µg/kg/day (Monier-Faugere
et al 1993). Lower doses were not effective and higher doses
resulted in a plateau. In the same experimental model,
treatment with ibandronate was started 4 months after OHX
when significant trabecular bone loss and increased
trabecular separation (p ≤ 0.05 for both) had already been
demonstrated, as well as significant increases in bone
turnover and activation frequency (Monier-Faugere et al
1999). Daily (5 of 7 days) and intermittent (on/off weeks = 2/
11) ibandronate administration at ≥ 4.1 µg/kg/day prevented
further bone loss while the highest dose 14 µg/kg/day
reversed bone loss completely to baseline values irrespective
of whether the continuous or cyclical regimen was used.
All doses induced a significant decrease in bone turnover
and activation frequency.
Preclinical evidence of preventive treatment with
ibandronate was established in studies using OVX monkeys.
Intravenous (IV) ibandronate was administered the day after
surgery with 10, 30, or 150 µg/kg given every 30 days for a
duration of 16 months (Smith et al 2003; Müller et al 2004).
The interval reflects the bone remodeling interval in
monkeys (approximately 1/3 of humans) and thus, 16
months is equivalent to 4 years of treatment in humans. OVX
induced a decrease in spine and femoral bone mineral
density (BMD) and a decrease in trabecular BMD in the
proximal tibia and distal radius. As compared with OVX-
controls, ibandronate revealed significant dose-related
suppression of activation frequency and the rate of bone
turnover, and prevented the OVX-induced loss of bone mass
in trabecular bone, with a somewhat lesser effect on cortical
bone. In general, ibandronate prevented all OVX-induced
changes dose-dependently with the 10 µg/kg dose expressing
suboptimal effects, the 30 µg/kg dose being the optimal dose
(not different from controls) at clinically relevant sites, and
the 150 µg/kg dose showing further increases in bone mass
and strength.
In all species tested, there was consistency regarding
normalization of bone turnover, prevention of bone loss,
trabecular separation (an indicator for trabecular connec-
tivity and architecture), and normal bone mineralization.
Data from preclinical studies suggest the total cumulative
dose administered over a period of time is more important
for efficacy than the treatment schedule itself. Although a
total dose concept was demonstrated by SC administration
only, the similar ibandronate concentrations in bone
following SC and oral administration after correction for
bioavailability suggest the total cumulative dose over time
will also be important for the oral regimen (Hoffman-La
Roche, Basel, Switzerland data on file).
Bone quality
Improved bone strength is an essential prerequisite for long-
term clinical use of bisphosphonates and is influenced by
several factors, including BMD, bone microarchitecture, and
bone defect repair. When assessed by biomechanical tests
(compression of predominantly cancellous bone; 3-point
bending of cortical bone; torsion of long bones), bone quality
was maintained or improved, even when using doses of
ibandronate far in excess of any therapeutically intended
dose. Bone strength also positively correlated with bone
density and architecture. The consistent positive correlationTherapeutics and Clinical Risk Management 2006:2(1) 7
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between bone mass or BMD with bone strength is in
accordance with the reported inverse relationship of fracture
incidence and BMD (Wasnich and Miller 2000; Hochberg
et al 2002).
In an interventional 12-month study in OVX rats, 3-point
bending tests in femur shafts and compression tests in
lumbar vertebrae were used (Bauss, Lalla, et al 2002). The
clear reduction in femoral bone strength between sham- and
OVX-controls (p ≤ 0.05) was dose-dependently prevented
by ibandronate, with the daily dose of 0.2 µg/kg being
optimal. In general, daily administration and cyclical
intermittent administration (all resulting in the same total
dose) produced equivalent results. Correlation between
lumbar ultimate load to failure (Fmax) and dual-energy
X-ray absorptiometry (DXA) or peripheral quantitative
computed tomography (pQCT) was r = 0.88 (p ≤ 0.0001 for
both), while DXA and pQCT results correlated by r = 0.89
(p ≤ 0.0001). Correlation of femoral Fmax versus cortical bone
density was 0.61 (p ≤ 0.0001). Increased trabecular
separation (p ≤ 0.0001) was fully prevented by all doses.
In the monkey study (Smith et al 2003; Müller et al
2004), biomechanical strength testing was performed on the
whole vertebrae, vertebral cores, ulna, humerus cortical
beams, and femoral necks and significant correlations
between BMD and bone strength were determined.
Ibandronate dose-dependently prevented the OVX-induced
loss of bone strength in all bones. The 30 µg/kg dose was
deemed to be the optimal dose based upon the most relevant
parameters. At 30 µg/kg, the biomechanical properties of
cancellous bone were normal with a somewhat lesser
effect on cortical bone. Importantly, a 5-fold higher dose
(150 µg/kg) had no adverse consequences on biomechanical
properties and showed a further increase in bone mass and
strength. Similarly, when alendronate was administered to
OVX monkeys, no significant changes were observed in
the femoral neck with regard to biomechanical properties
whereas BMD was increased (although less pronounced than
compared with ibandronate) (Balena et al 1993). The smaller
effect of both bisphosphonates on bone sites with
predominantly cortical bone is consistent with the lesser
uptake of both drugs by bones consisting of predominantly
cortical bone when compared with those consisting of
predominantly trabecular bone (Lin et al 1992; Bauss and
Russell 2004).
In the 2-year carcinogenicity study in intact rats (Lalla
et al 1998), bone quality was investigated in vertebrae and
femurs after daily dosing of up to 15 mg/kg. Compressive
strength and stiffness were significantly higher in
ibandronate-treated animals, whereas no changes occurred
in strain or modulus of elasticity. A highly significant
correlation was found between maximal strength in vertebral
bodies and BMD measured either by DXA (r = 0.86) or
pQCT (r = 0.85) (both p < 0.0001). Femur analyses revealed
increased bone strength in cortical as well as in cancellous
bone.
In a long-term study in skeletally mature intact dogs,
administration of ibandronate at a dose that is therapeutically
active in OVX dogs (1 µg/kg/day) (Monier-Faugere et al
1993) did not impair bone repair or any other biomechanical
parameters (Bauss et al 2004). In this study, animals were
administered SC ibandronate either daily or in two cyclical
intermittent regimens (1 week “on” and 2 or 6 weeks “off”)
to provide the same total dose at the end of the study. Healing
of drill hole defects (tibia), which simulates the first stage
of fracture healing as well as the internal remodeling of
bone (femur) that occurs in the later stages of fracture
healing, was neither qualitatively nor quantitatively
influenced by ibandronate. Biomechanical analyses in
vertebrae, indentation tests in the metaphyses, and 3-point
bending of cortical beams did not produce significant
differences in any group.
Bone safety
In preclinical studies no adverse effects on bone minerali-
zation and biomechanical properties have been observed
with ibandronate, even at doses several orders of magnitude
above therapeutically active levels.
Unlike etidronate, no impairment of bone mineralization
is expected for the more potent N-containing bisphos-
phonates. In OHX dogs administered ibandronate, no
osteomalacia and no overt defective mineralization of
osteoid was observed at 100-fold higher dose than the
preventive dose of 1 µg/kg/day (Monier-Faugere et al 1993),
which indicates a relatively wide therapeutic margin. When
ibandronate was repeatedly administered in intact growing
rats, mineralization was not affected in woven or lamellar
bone, or in cartilage (Mühlbauer et al 1991). The highest
ibandronate dose tested in this respect (1.0 mg P/kg/day SC,
corresponding to 5.14 mg free acid equivalents/kg) was
found to be > 5000 times the therapeutic dose used in
osteoporosis (Bauss, Lalla, et al 2002; Bauss, Wagner, et al
2002).Therapeutics and Clinical Risk Management 2006:2(1) 8
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The highest cumulative dose of ibandronate administered
SC in OVX rats (9.125 mg/kg) was associated with normal
bone quality (Bauss, Lalla, et al 2002). Assuming an average
weight of 65 kg for an osteoporotic woman, this total dose
equates to 593 mg. Thus, using a clinical ibandronate
regimen (3 mg every 3 months IV) (Recker et al 2004),
which results in a 12 mg annual exposure, the same total
ibandronate exposure in patients would require a treatment
period of about 50 years. A similar calculation for oral
dosing, using the total maximal oral exposure in rats
(approximately 9.7 mg/kg), which provided maintained or
increased bone quality (Lalla et al 1998), would correspond
to a treatment period of 350 years for a once-monthly oral
150 mg regimen in osteoporotic women (assuming similar
bioavailability over time).
These preclinical findings support the conclusion that
bone quality will most likely not be adversely affected during
long-term treatment with ibandronate in humans, even with
doses exceeding the therapeutic range by multiples.
Clinical development: dose-finding
for daily administration of
ibandronate
A phase II dose-finding study for the oral daily adminis-
tration of ibandronate represented the first step in the clinical
development program (Ravn et al 1996; Schimmer and
Bauss 2003). The study included 180 postmenopausal
women (time since menopause > 10 years) with low bone
mass as determined by a distal forearm BMD T-score < –1.5.
Patients were randomized to receive either placebo, or daily
doses of oral ibandronate of 0.25 mg, 0.5 mg, 1.0 mg, 2.5 mg,
or 5 mg. All patients received 1000 mg calcium daily. Dose-
proportional increases in lumbar spine BMD were observed
after 1 year, which were all significantly different from
placebo with the exception of the lowest dose tested
(0.25 mg). The top of the dose-response was reached with
the 2.5 mg daily dose; the higher 5.0 mg dose did not show
additional benefits. Daily ibandronate 2.5 mg produced
increases in lumbar spine BMD relative to baseline of 4.6%,
1.9% at the total proximal femur, 3.1% at the trochanter,
and 2.5% at the femoral neck. For this dose, highly
significant (p < 0.001) changes in lumbar spine BMD
compared with baseline were observed as early as 3 months.
The dose-relationship was also apparent in the reduction of
biochemical markers of bone turnover. Urinary C-telopeptide
of the α-chain of type I collagen (CTX) was reduced by
74% and serum osteocalcin by 33% relative to baseline after
1 year of treatment with 2.5 mg daily oral ibandronate.
Significant reductions of these markers were observed as
early as the first measurement point (3 months, p < 0.001).
On the basis of these results 2.5 mg was determined to
represent the optimum therapeutic dose for the daily oral
administration of ibandronate.
Feasibility of ibandronate
administration with longer (>2
months) dose-free intervals
Based on the potency and safety characteristics of
ibandronate, the intermittent administration of this
bisphosphonate with longer dose-free intervals has been the
main focus of the clinical development program.
Consequently, a second phase II study was established to
explore and compare the daily regimen with a new
intermittent regimen featuring a greater than 2 month dose-
free interval in order to assess the clinical feasibility of such
usage (Riis et al 2001). This comparative, equivalence trial
randomized 240 postmenopausal women with a BMD
T-score < –2.5 at either the lumbar spine or the hip into three
treatment groups: placebo and either daily oral ibandronate
2.5 mg or 20 mg every other day for 12 doses every 3 months,
a regimen which thus comprised a dose-free interval of
9–10 weeks. This intermittent regimen was composed to
deliver, in principle, the same cumulative dose over a
3-month period as the daily administration of 2.5 mg
(approximately 225 mg for daily and 240 mg for
intermittent). All patients received 500 mg calcium and
400 IU vitamin D supplementation. The trial succeeded in
demonstrating statistically equivalent BMD gains at the
lumbar spine after 2 years (5.6% vs 5.5% for the daily and
intermittent regimens, respectively). Also the hip BMD gains
were nominally identical (3.4% both regimens).
Markers of bone resorption and bone formation were
reduced to a similar degree with both regimens. Typically,
the steady state of reduction of markers of bone resorption
with bisphosphonate treatment is seen after 3–6 months.
Mean reduction of urinary N-telopeptide of the α-chain of
type I collagen (NTX), for example, was 58% after 6 months
for daily ibandronate and 50% for intermittent ibandronate.
Similarly, mean relative reduction of this marker after 1 year
was 58% for daily and 50% for the intermittent regimen
(Riis et al 2001; Roche data on file). Mean relative reduction
of serum osteocalcin for daily and intermittent ibandronate
was 35% and 32%, respectively, after 6 months, and 42%
and 38%, respectively, after 1 year.Therapeutics and Clinical Risk Management 2006:2(1) 9
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Ibandronate was well tolerated and both regimens
showed an adverse event profile comparable with placebo.
This is particularly noteworthy for the intermittent regimen,
since it provided an overall larger dose within a given time
frame (240 mg within 24 days as opposed to 60 mg within
24 days with the daily dose) but did not result in any
meaningful difference of adverse events compared with
placebo (Riis et al 2001; Schimmer and Bauss 2003).
Antifracture efficacy with daily and
intermittent oral ibandronate
Osteoporotic fractures are the individually, clinically, and
economically most relevant pathological element of
osteoporosis. For an antiosteoporotic medicine to be made
available to physicians and patients, antifracture efficacy in
postmenopausal osteoporosis must be demonstrated. Drug
approval authority guidelines state that the assessment of
the effect of a new drug regimen on the incidence of new
vertebral fractures is of primary importance in judging
efficacy (FDA 1994). Consequently, trials investigating the
effect on new morphometric vertebral fractures after 3 years
of treatment are required for efficacy demonstration. Such
trials have been conducted for all currently approved
N-containing bisphosphonates (alendronate, risedronate,
and ibandronate) (Black et al 1996; Harris et al 1999;
Chesnut et al 2004). All of these trials were performed using
a daily administration of the respective bisphosphonate, as
was also the case for ibandronate with its daily form
receiving approval and registration for the treatment and
prevention of postmenopausal osteoporosis.
However, antifracture efficacy for current weekly
regimens of alendronate or risedronate has not been
demonstrated, and approval of these regimens was granted
based on the demonstration of therapeutic equivalence of
weekly and daily regimens for the surrogate marker BMD
at the lumbar spine. This was derived from the biological
and pharmacological understanding that the administration
of a single dose of a bisphosphonate within a period of up
to 2 weeks represents a continuous and not an intermittent
treatment (Bone et al 2000; Cremers et al 2005].
In the case of ibandronate, specifically aiming at dose-
free intervals longer than weekly, such an extrapolation
would not be appropriate, and therefore direct demonstration
of antifracture efficacy with a truly intermittent regimen was
pursued in addition to the daily form. Thus, the phase III
fracture trial of ibandronate is uniquely different from other
phase III osteoporosis trials in that it included not only a
daily regimen, but also, as proof of principle, the intermittent
regimen explored in phase II studies with a dose-free interval



















































Figure 2 Variability of vertebral fracture rates in recent phase III studies of osteoporosis and established osteoporosis (Kanis et al 2003).Therapeutics and Clinical Risk Management 2006:2(1) 10
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Antifracture efficacy of ibandronate –
vertebral fractures
A total of 2946 patients were included in the phase III trial
(BONE – Oral iBandronate Osteoporosis vertebral fracture
trial in North America and Europe) and randomized to
placebo, 2.5 mg daily oral ibandronate, or 20 mg intermittent
oral ibandronate (Chesnut et al 2004). Calcium and
vitamin D were supplemented at doses of 500 mg and
400 IU, respectively. The inclusion criteria specified a
lumbar spine BMD T-score < –2.0 in at least 1 vertebra and
at least 1 prevalent vertebral fracture, and were thus very
similar to other trials with N-containing bisphosphonates
or other antiresorptive compounds (Black et al 1996;
Ettinger et al 1999; Harris et al 1999). In this context, it is
of interest to compare the actual fracture risk across such
trials. Despite very similar inclusion criteria a wide
variability of fracture risk can be observed (Figure 2) (Kanis
et al 2003). The population recruited for the BONE study
was shown to have the lowest fracture risk of all these
osteoporosis trials to date. Nevertheless, ibandronate proved
to be highly effective and daily ibandronate reduced the
incidence of new morphometric vertebral fractures
significantly from 9.6% in the placebo group to 4.7%
(p = 0.0003). This translated into a relative risk reduction of
62% (p = 0.0001). Ibandronate demonstrated a very
consistent effect with relative risk reductions of 58% (95%
confidence interval [CI]: 83, –2) after 1 year, 61% (95% CI:
77, 33) after 2 years and 62% (95% CI: 75, 41) after 3 years
(Figure 3) (Chesnut et al 2004). Analysis of the fractures
using a semiquantitative (Genant et al 1993, 1996) rather
than a morphometric classification, corroborated the early
onset of the effect and the remarkable consistency for the
clinically most relevant moderate and severe vertebral
fractures. Relative risk reductions of 59% each after 1 year
(p = 0.0164), 2 years (p = 0.0004), and 3 years (p < 0.0001)
were observed (Figure 4) (Felsenberg et al 2005). Significant
reductions compared with placebo were also observed for
new and worsening vertebral fractures (62%, p = 0.0001) as
well as clinical (symptomatic) vertebral fractures (49%,
p = 0.0117).
Ibandronate also showed consistent risk reductions in
new vertebral fractures across a wide risk spectrum as
determined in post-hoc subgroup analyses. This was
demonstrated for the subgroups of the US vs the European
study population (Chesnut et al 2005), and also for additional
risk levels determined by number of baseline vertebral
fractures, baseline BMD T-score, and history of clinical
fractures (Figure 5) (Ettinger et al 2002).
The BONE trial also explored the primary endpoint of
new morphometric vertebral fractures for the intermittent
regimen with a dose-free interval of 9–10 weeks. This
ibandronate regimen succeeded in reducing the incidence
of new vertebral fractures to 4.9% (p = 0.0005) compared
with placebo (9.6%), which translates into a relative risk
reduction of 50% (p = 0.0006). The difference between the
daily and the intermittent regimen was not statistically
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Figure 3 Cumulative effect of oral daily ibandronate on new vertebral fractures





















































































Figure 4 Relative-risk reductions for new moderate and severe vertebral
fractures at years 1, 2, and 3 (Felsenberg et al 2005). Reprinted from Bone, In
press. Felsenberg et al. 2005. Oral ibandronate significantly reduces the risk of
vertebral fractures of greater severity after 1, 2 and 3 years in postmenopausal
women with osteoporosis. Copyright © 2005, with permission from Elsevier.Therapeutics and Clinical Risk Management 2006:2(1) 11
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significant (p = 0.2785). This was the first prospective
demonstration of antifracture efficacy for a bisphosphonate
regimen other than daily and proof of principle that fracture
prevention is possible with ibandronate administered with
longer dose-free intervals.
Antifracture efficacy of ibandronate –
nonvertebral fractures
Clinical osteoporotic fractures (including clinical vertebral
and all nonspine fractures except fingers and toes) and
nonvertebral fractures (including all of the former without
vertebral fractures) were explored as secondary endpoints
in the study. Like other similarly designed osteoporosis
trials, the BONE study was adequately statistically powered
to demonstrate between group differences for the primary
endpoint of new vertebral fractures (FDA 1994; CPMP
2001), but not for nonvertebral fractures. To date, very few
trials have been designed and statistically powered to detect
an effect on nonvertebral fractures as a primary endpoint.
The Hip Intervention Program study, to date the only trial
specifically designed to study the effect on hip fractures,
investigated the effects of risedronate and included almost
10 000 patients (6197 received risedronate, 3134 received
placebo) (McClung et al 2001), while a recently published
study on the effect of strontium ranelate on nonvertebral
fractures randomized 5091 (2554 received strontium
ranelate, 2537 received placebo) patients (Reginster,
Seeman, et al 2005). Otherwise, effects on nonvertebral
fractures or individual peripheral fractures for the N-
containing bisphosphonates risedronate and alendronate
could be shown through enlarged analysis populations, with
increased statistical power, by pooled meta-analyses
(Cranney, Wells, et al 2002; Cranney, Tugwell, et al 2002;
Harrington et al 2004; Papapoulos et al 2005).
Efficacy on nonvertebral fractures has not been
consistently demonstrated in the overall study population
of individual osteoporosis trials (Marcus et al 2002; Delmas
and Seeman 2004), which were usually designed and
powered to detect treatment effects on vertebral fractures.
In numerous studies, no significant effects on nonvertebral
fractures have been observed, for example, with the licensed
N-containing bisphosphonates alendronate and risedronate
(Liberman et al 1995; Black et al 1996; Cummings et al
1998; Reginster et al 2000). However, in this situation,
subgroup analyses exploring patients at higher risk than the
Figure 5 Reduction in relative risk with oral daily ibandronate (± 95% CI) of first new incident vertebral fracture through year 3 across various risk levels (intent-to-
treat population) (adapted from Ettinger et al 2002).Therapeutics and Clinical Risk Management 2006:2(1) 12
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average overall population have been shown to be helpful
to elucidate and characterize the effect of a compound on
such fractures. For example, the effect of alendronate on all
clinical osteoporotic fractures in a study with more than
4400 patients with low BMD, but without prevalent vertebral
fractures, could not be demonstrated at a statistically
significant level in the overall population (Cummings et al
1998), but in patients with lower BMD at the femoral neck
(T-score < –2.5), the drug did show a significant risk
reduction. In the Hip Intervention Program study (n = 9331)
risedronate reduced the risk of hip fractures by 40% in the
subgroup of patients with low femoral neck BMD (T-score
< –3.0) plus at least 1 risk factor for hip fracture or BMD
T-score < –4.0, but not in the older (≥ 80 years of age) patients
in this study, which were primarily selected on the basis of
clinical risk factors for hip fracture alone (McClung et al
2001). Similarly, strontium ranelate showed a significant
effect on nonvertebral fractures in a study designed and
powered (n = 5091) to assess this endpoint (Reginster,
Seeman, et al 2005), but not hip fractures. However, again
in patients with lower femoral neck BMD (T-score < –3.0)
which showed a higher incidence of hip fractures, the
compound did demonstrate a significant effect in a post-
hoc analysis.
In parallel with these observations, the effect on clinical
osteoporotic and nonvertebral fractures was also not
significant with ibandronate in the BONE study (Chesnut
et al 2004), in which enrolled patients had also a very low
fracture risk level compared with those in other trials. A
significant effect on nonvertebral fractures of consistent
magnitude was observed in post-hoc analyses, however, in
subgroups of patients at higher risk and thus with a higher
incidence of these fractures. A 69% relative risk reduction
was seen in patients with low BMD as defined by a femoral
BMD T-score below –3.0 (p = 0.013 vs placebo). Also in
patients with a lumbar spine BMD T-score < –2.5 and a
history of clinical fractures in the previous 5 years, a
significant 60% relative risk reduction of nonvertebral
fractures was shown (p = 0.0371) (Roche and GSK data on
file). These criteria correspond with the majority of patients
typically treated for postmenopausal osteoporosis in many
European countries.
Effects of daily oral ibandronate on
bone turnover and BMD
The ibandronate antifracture efficacy described above is
based on the common mode of action of all bisphosphonates:
the reduction of bone resorption through their direct effects
on osteoclasts. Daily ibandronate reduced markers of bone
resorption (urinary CTX and urinary NTX) significantly to
a steady state level of approximately 65%–70% (Delmas,
Recker, et al 2004), and serum osteocalcin to a level of
approximately 40%.
This sustained reduction resulted in substantial and
significant gains in BMD at the lumbar spine (6.5%) and
the total hip (3.4%) after 3 years (p < 0.0001 at all sites
compared with placebo). It is also important to characterize
the effect of a bisphosphonate on the reduction of bone
turnover and subsequent BMD increase. Based on the
common mechanism of action, these surrogate parameters
can provide additional information about antifracture
efficacy, which may not be possible to obtain through the
primary fracture endpoint of the study. For such scientific
extrapolations it is necessary to demonstrate a clear
relationship between treatment-induced BMD gains and
fracture effect. Such a relationship has been demonstrated
for ibandronate using a surrogate marker analysis which
has quantified the fraction of fracture effect explained solely
by BMD (Wasnich et al 2003).
Class efficacy of nitrogen-containing
bisphosphonates
The N-containing bisphosphonates like ibandronate,
alendronate, or risedronate share a common mechanism of
action and many large clinical trials have demonstrated
consistent and similar effects on reduction of bone turnover,
increases in BMD, and reduction in vertebral fractures.
Effects on nonvertebral fractures, including hip fractures,
were shown in a less consistent way as indicated above,
mostly due to the fact that the individual osteoporosis trials
were not designed and powered to demonstrate effects on
these fractures. Meta-analyses and the use of surrogate
markers for efficacy, ie, BMD and biochemical markers of
bone turnover together with the demonstration of a clear
relationship between bisphosphonate-induced increases in
BMD and reduction in bone resorption markers to
antifracture efficacy for vertebral as well as nonvertebral
fractures (Wasnich and Miller 2000; Hochberg et al 2002),
corroborate the understanding of a similar effect of this class
on all these fractures.
The magnitude of treatment effect between the
individual bisphosphonates may show some degree of
variability, particularly for BMD and bone turnover
reduction (Rosen et al 2005a), and this variability likely
depends on several factors such as potency, dose, and bone-
binding characteristics. Different effect sizes for BMD andTherapeutics and Clinical Risk Management 2006:2(1) 13
Ibandronate: the first once-monthly oral treatment for osteoporosis
bone marker reduction, as recently shown for alendronate
and risedronate (Rosen et al 2005a), do appear to matter
when individual patients rather than group levels are
considered by means of responder analyses. Here, larger
treatment effects translate into more patients responding
favorably to treatment, which is likely to result in an
improved protection from osteoporotic fractures for these
patients.
Effects of daily oral ibandronate in
the prevention of postmenopausal
osteoporosis
Oral daily ibandronate has also been explored for the
prevention of osteoporosis in postmenopausal women at risk
for developing osteoporosis. For this purpose a phase II/III
trial was conducted in 653 women with either normal bone
mass or women with osteopenia. Three doses were tested
in this trial, 0.5 mg, 1.0 mg, and 2.5 mg administered daily
over 2 years with the primary endpoint of relative change
in lumbar spine BMD. The study demonstrated dose-
dependent effects of ibandronate, with the 2.5 mg dose
showing not only prevention of bone loss but significant
increases of BMD at the lumbar spine and the hip (McClung
et al 2004). Correspondingly, dose-dependent decreases in
markers of bone resorption and formation were observed.
Based on the described studies and the demonstration
of its robust characteristics, daily oral ibandronate at a dose
of 2.5 mg was approved for the treatment and prevention of
postmenopausal osteoporosis by the health authorities in
the US and Europe in 2003.
Development of once-monthly oral
ibandronate
Dose range determination for once-
monthly ibandronate
The development of a single once-monthly tablet of
ibandronate for the treatment of osteoporosis had to integrate
the outcomes and insights of the ibandronate development
program in order to define monthly doses that would deliver
optimal efficacy relative to this particular dose-free interval.
The impact of extending the dose-free interval beyond daily
was observed in the preclinical development program (Bauss
and Russell 2004). This reflected a slight decline in effect
size, which was positively related to the length of the dose-
free interval. Also in clinical trials of alendronate or
risedronate (Figure 6), this effect decrease was apparent
when moving from daily to weekly intervals, though again
not statistically significant or clinically relevant (Schnitzer
et al 2000; Brown et al 2002; Harris et al 2002; Rizzoli et al
2002). In the BONE trial, this effect was noted when
comparing treatment effect magnitudes of the daily regimen
with the intermittent regimen with a dose-free interval of
more than 2 months. Given the large variability of the effect
size in humans, a clear need existed to optimize the treatment
effect size for a once-monthly regimen of ibandronate by
increasing the dose to compensate for this commonly
observed loss of effect over time. Using a 4-compartment
model combined with an indirect response
pharmacodynamic model (Pillai et al 2004), the effect of
monthly dosing intervals of various doses of ibandronate
could be simulated (Gieschke and Reginster 2004). This
laid the foundation for the decision of dose increases of up
to 100% compared with the cumulative monthly dose of
the daily regimen resulting in once-monthly doses of
ibandronate of 100 mg and 150 mg being tested clinically.
Clinical feasibility of once-monthly
ibandronate dosing – the MOPS study
Following the comprehensive characterization of efficacy
and safety of daily as well as intermittent ibandronate, the
development of a unique once-a-month tablet was started
in order to further reduce the dosing frequency compared
with established daily and weekly regimens and thus support
daily alendronate (10 mg)
weekly alendronate (70 mg)
daily risedronate (5 mg)








































Figure 6 Impact of extending the dose-free interval from daily to weekly on
efficacy for alendronate and risedronate (Schnitzer et al 2000; Brown et al
2002).Therapeutics and Clinical Risk Management 2006:2(1) 14
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patients and physicians towards long-term improvement of
adherence to treatment.
The principal feasibility of a once-monthly ibandronate
dose regarding safety and tolerability and the effect on bone
turnover was explored in a phase I pilot double-blind,
placebo-controlled study (MOPS – Monthly Oral Pilot
Study) (Reginster, Wilson, et al 2005). The study
randomized 144 postmenopausal women aged 55–80 years
and > 3 years postmenopause. Three once-monthly doses
were investigated in the study: 50 mg, 100 mg, and 150 mg
without additional calcium and vitamin D supplementation
over a study duration of 3 months. Monthly ibandronate
was well tolerated with a safety and tolerability profile
comparable with placebo, despite the higher doses used.
This was particularly noteworthy for GI tolerability, which
again was similar to placebo.
Monthly ibandronate also showed dose-dependent
decreases in serum CTX, a marker of bone resorption.
Analysis of the area under the effect curve (AUEC over days
1–90) for the median relative change (% × days) in both,
serum and urinary CTX revealed a dose-dependent effect
of monthly ibandronate, with the 150 mg dose showing the
most pronounced treatment effect size. Based on these
outcomes and the very good safety and tolerability observed
for the monthly doses in this trial, the development was
moved forward to a phase III comparative trial aiming to
demonstrate therapeutic equivalence to the daily regimen
with its proven antifracture efficacy.
Demonstration of therapeutic
equivalence of once-monthly
ibandronate to daily – the MOBILE
study
Once antifracture efficacy has been established, usually for
the daily administration of a bisphosphonate as done for
the class of N-containing bisphosphonates ibandronate,
alendronate, and risedronate, further modified adminis-
tration regimens with the respective molecule can achieve
regulatory approval based on the demonstration of
therapeutic equivalence of the new regimen with the
established regimen. This therapeutic equivalence can be
based on a surrogate parameter for antifracture efficacy, in
this case BMD at the lumbar spine. Examples for this
procedure include the introduction of the weekly regimens
for alendronate and risedronate. For both regimens, no
antifracture efficacy data have been generated, but trials
comparing the weekly regimens with the respective daily
regimen were sufficient to obtain regulatory approval.
Therapeutic equivalence may be based on statistical
equivalence (Schnitzer et al 2000) or noninferiority (Brown
et al 2004).
The same approach was taken for monthly ibandronate,
namely comparing the new once-monthly regimens with
established daily ibandronate which has demonstrated
antifracture efficacy for vertebral and nonvertebral fractures.
For this purpose, the MOBILE study (Monthly Oral
iBandronate In LadiEs) randomized 1609 postmenopausal
women with baseline BMD T-scores at the lumbar spine
below –2.5 into 4 treatment arms: 2.5 mg daily, 100 mg
monthly administered as 50 mg single doses over 2
consecutive days, 100 mg monthly on a single day, and
150 mg monthly on a single day (Miller et al 2005). All
patients also received 500 mg calcium and 400 IU vitamin D.
The primary endpoint was the relative change in lumbar
spine BMD after 1 year. The study analyzed additional
secondary endpoints like BMD at the hip sites, reduction in
serum CTX, a marker of bone resorption and responders to
treatment for various cut-offs of BMD increases and bone
resorption maker reductions. Therapeutic equivalence of
monthly to daily regimens was assessed by a noninferiority
analysis using a prespecified, conservatively defined
noninferiority margin.
The study succeeded in clearly meeting the primary
endpoint by demonstrating noninferiority for both monthly
doses (Figure 7). Moreover, the compensatory dose increase
of the monthly regimen resulted in even larger BMD
increases compared with the daily regimen, which, in the
case of the 150 mg dose, were statistically superior. The
observed BMD increases were dose-dependent in their
magnitude. In a similar fashion, dose-dependent BMD
increases were also observed at all hip sites, with the 150 mg
dose showing the largest gains again. Noninferiority, based



































































Figure 7 Forest plot of the difference in the means (95% confidence interval)
of the mean percent change from baseline in lumbar spine (L2–L4) bone mineral
density between the monthly and daily oral ibandronate regimens after 1 year
(per protocol population) (Miller et al 2005).Therapeutics and Clinical Risk Management 2006:2(1) 15
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In addition, this dose also demonstrated superiority at all
hip sites, except the femoral neck.
Further to BMD increases assessed at study group level,
analyses were also performed at the individual patient level
using responder analyses. Several responder definitions were
applied, for preservation of BMD or increases above
baseline; for increases above 6% at the lumbar spine, for
increases above 3% at the total hip, and for combined spine
and hip BMD increases above baseline. For all these
responder analyses the 150 mg once-monthly dose showed
the largest percentage of patients falling above the targets;
thus the 150 mg dose consistently provided treatment
benefits for the largest number of patients.
Serum CTX, a marker of bone resorption was decreased
rapidly and subsequently sustained at the lower level
throughout the study. While the 100 mg dose achieved
similar reductions to the daily ibandronate dose, the 150 mg
dose improved reduction by, approximately, a further 10%
of the median levels. Given the reported linear relationship
between bone marker reduction and in particular non-
vertebral antifracture efficacy (Hochberg et al 2002; Eastell
et al 2003; Rosen et al 2005b), the demonstrated efficacy
performance of the 150 mg monthly dose indicates the
potential for greater patient benefits.
Safety and tolerability (BONE and
MOBILE)
The safety and tolerability of oral ibandronate have been
monitored continuously during all of the trials included
within the clinical development program. Such data have
therefore been collected for ~3500 patients, providing an
extensive safety profile (Ravn et al 1996; Riis et al 2001;
Chesnut et al 2004; Miller et al 2005).
The adverse event profile for daily and intermittent
ibandronate regimens studied in the phase II studies was
similar to placebo; this is notable given the 8-fold higher
single dose administered for the intermittent regimen. The
incidence of GI adverse events was also comparable with
placebo, even in patients with a history of GI disturbance
(Ravn et al 1996; Riis et al 2001; Schimmer et al 2003).
A large patient population (n = 2929) was included in
the BONE study and has therefore allowed a detailed
evaluation of the safety and tolerability profile of daily and
intermittent oral ibandronate (Chesnut et al 2004). The
overall analysis indicated that both regimens were well
tolerated and the safety profiles were similar to placebo. In
summary, 89%–92% of patients experienced at least one
adverse event, only 18%–20% had an adverse event that
was considered to be treatment-related, and ≤ 25%
experienced an adverse event that was classified as serious
(22%–25%). A subgroup analysis by age indicated that
elderly patients (aged ≥ 70 years) were not at any greater
risk of adverse events (Ettinger et al 2005). The number of
patients withdrawing from the study due to a treatment-
related adverse event was comparable in the placebo (8.1%)
and ibandronate groups (7.5% and 7.2% for the daily and
intermittent groups, respectively).
Ibandronate administration was not associated with an
increased incidence of GI adverse events either in the overall
population or a subgroup of patients at increased risk for
upper GI events (Chesnut et al 2004). Approximately 30%
of the overall population had a history of upper GI disorders,
and approximately 60% were taking concomitant non-
steroidal antiinflammatory drugs (NSAIDs). The number
of dyspepsia, gastroenteritis, and nausea events, within these
subgroups, was similar for placebo and the two treatment
groups (15%–20%, 6%–9%, and 7%–9%, respectively in
patients with a history of upper GI disorders; 11%–15%,
6%–7%, and 4%–7%, respectively in patients taking
NSAIDs) (Rosen et al 2003).
The safety and tolerability of the once-monthly regimens
were assessed throughout the MOBILE study (Miller et al
2005). The safety population of all patients taking at least 1
dose of study medication with one follow-up data point,
equaled 1583 women. The overall incidence of adverse
events was comparable between the daily and once-monthly
treatment groups: 67%–70% of patients in each group
experienced at least one adverse event. Approximately 1
third of patients had an adverse event that was considered
treatment-related (27%–33%), with only 6 patients having
drug-related serious adverse events. The number of patients
withdrawing from the study due to a treatment-related
adverse event was similar in the once-monthly and daily
groups (5%–7%).
When GI adverse events were considered separately
there was no difference in the overall incidence between
the groups (18%, 15.9%, 21.7%, and 16.9% in the 2.5 mg,
50 + 50 mg, 100 mg, and 150 mg groups, respectively). A
subgroup analysis was also completed in this study,
including patients with a history of upper GI disorders or
taking concomitant NSAIDs. With 1 exception, the number
of patients experiencing upper GI adverse events was
comparable across the treatment groups (37%–46% in
patients with a history of upper GI disorders; 18%–25% in
patients taking NSAIDs). The number of patients with aTherapeutics and Clinical Risk Management 2006:2(1) 16
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history of upper GI disorder experiencing an upper GI
adverse event was lower in the 150 mg group (19.6%).
The data from the BONE and MOBILE studies
confirmed that oral ibandronate is well tolerated in women
with postmenopausal osteoporosis. It was also demonstrated
that there is no safety disadvantage between the daily
ibandronate dose (2.5 mg) and the larger single doses
(150 mg) required for once-monthly dosing.
Taken together, the consistently greater treatment effects
of the 150 mg once-monthly dose compared with the 100 mg
dose and lack of any safety disadvantage, led to marketing
applications for the 150 mg dose being filed with the US
and European health authorities and subsequently approval
was received in March and September 2005, respectively.
Conclusion
Ibandronate is a new N-containing bisphosphonate which
has been developed specifically for administration with long
dose-free intervals and which has recently been approved
in the US and Europe for a unique once-monthly oral
regimen. The comprehensive preclinical development
program for ibandronate in estrogen-depleted rats, dogs, and
monkeys has demonstrated the feasibility and therapeutic
equivalence of intermittent dosing compared with
continuous dosing for ibandronate for the same total
cumulative dose administered over a given time period.
Ibandronate was shown to dose-dependently improve or
preserve bone mass, bone turnover, architecture, and bone
strength. Bone quality and bone safety have been maintained
or improved even with doses far exceeding the therapeutic
range. These studies, which followed the guidelines of drug
approval authorities for development of antiosteoporotic
drugs, provided a sound basis for intermittent treatment of
women with postmenopausal osteoporosis. The once-
monthly regimen of ibandronate can be expected to deliver
at least the robust antifracture efficacy documented in the
BONE study (Chesnut et al 2004) for vertebral and
nonvertebral fractures. Antifracture efficacy has also been
demonstrated for the first time with a bisphosphonate for
intermittent treatment, with ibandronate administered with
a dose-free interval of more than 2 months. Once-monthly
ibandronate has been shown to be therapeutically equivalent
and even superior to daily ibandronate for BMD gains at
the lumbar spine and the hip with good safety and
tolerability. This convenient once-monthly regimen, which
is linked with strong patient preference over a weekly
administration (Simon et al 2005), promises to further
support and improve therapeutic adherence to
bisphosphonate treatment.
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